Representative Sofimac Innovation
François Miceli started his career in one of the first French public biotechnology companies called Clonatec within OHF Holding group, where he served as International Product Manager. At the end of 1990, François joined the US NASDAQ listed company Idexx Laboratories Incorporated where he successively served as Director for Europe in an international business unit, General Manager of the French subsidiary Idexx France S.A and then CEO of the Italian subsidiary Idexx Laboratories Italia.
Back to France in 1998, François joined Synbiotics, spin-off from Merial as Director of European Operations before founding LMD Pharma, a biotech start up with the support of several major venture capital funds such as BANEXI Ventures, LCF Rothschild, Siparex and Sofimac Partners. From 2003 to 2011, François served as CEO of the integrated biopharmaceutical company Imaxio dedicated to innovative vaccines for infectious diseases and oncology. During this period, Imaxio received in 2009 the 3rd prize of Deloitte Fast 50 and the 2nd prize of Deloitte Fast 50 in 2010.
Since February 2011, François is founder and CEO of Zophis SAS, a French holding company dedicated to in-license early stage assets in the vaccine field. François now serves as Senior Investment Partner with Sofimac Partners where he is in charge of innovation investments. He is also member of the economic board of the vaccine cluster LyonBiopôle and of the industrial council of CLARA (Cancéropôle Auvergne Rhône-Alpes).
François Miceli graduated in biology engineering from Paris XII UPEC University, INSEAD (EE, Corporate Finance) and IHEDN (Institut des Hautes Etudes de Défense Nationale, promotion Chevalier Bayard).